ABVX ▲ +1.8% - ABIVAX Société Anonyme Abivax $ABVX has still not been acquired. What’s going on? Biotech M&A activity is off the charts, yet the French drugmaker — developer of obefazimod, a treatment for ulcerative colitis with blockbuster commercial potential — remains unbetrothed... The absence of said transaction has caused the stock’s investor fanbase much grief and consternation. -- ADAM F STAT NEWS Abivax rose 1.8% today as investors continue to wait for a potential acquisition of the French biotech company. The company's obefazimod, which has blockbuster potential for ulcerative colitis treatment, has made it an acquisition target in a period of active biotech M&A, though no deal has materialized yet. 03-SEP-2026 09:31 AM ET